These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37960990)

  • 1. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
    Choi H; Huang F; Flack M
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
    Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
    Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
    Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Jungnik A; Gansser D; Ebner T; Müller F
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):69-80. PubMed ID: 28685495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
    Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
    Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function.
    Stevens LJ; Dubbeld J; Doppenberg JB; van Hoek B; Menke AL; Donkers JM; Alsharaa A; de Vries A; Vaes WHJ; Knibbe CAJ; van de Steeg E; Alwayn IPJ
    Clin Pharmacol Ther; 2023 Jul; 114(1):137-147. PubMed ID: 37042227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study.
    Otani N; Wakuda H; Imai H; Kuranari M; Ishii Y; Ito Y; Okubo A; Ogawa O; Takeda K; Ohyama T; Hasunuma T; Uemura N
    Clin Transl Sci; 2019 Sep; 12(5):513-518. PubMed ID: 31095880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
    Grande E; Giovannini M; Marriere E; Pultar P; Quinlan M; Chen X; Rahmanzadeh G; Curigliano G; Cui X
    Br J Clin Pharmacol; 2021 Jul; 87(7):2867-2878. PubMed ID: 33300203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
    J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.
    Katsube T; Miyazaki S; Narukawa Y; Hernandez-Illas M; Wajima T
    Eur J Clin Pharmacol; 2018 Jul; 74(7):931-938. PubMed ID: 29627897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.
    Wiebe ST; Giessmann T; Hohl K; Schmidt-Gerets S; Hauel E; Jambrecina A; Bader K; Ishiguro N; Taub ME; Sharma A; Ebner T; Mikus G; Fromm MF; Müller F; Stopfer P
    Clin Pharmacokinet; 2020 Dec; 59(12):1627-1639. PubMed ID: 32504272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
    Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
    Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
    Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
    J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.
    Trueck C; Hsin CH; Scherf-Clavel O; Schaeffeler E; Lenssen R; Gazzaz M; Gersie M; Taubert M; Quasdorff M; Schwab M; Kinzig M; Sörgel F; Stoffel MS; Fuhr U
    Clin Pharmacol Ther; 2019 Dec; 106(6):1398-1407. PubMed ID: 31247117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.